Compositions and methods for combination pharmacological treatments to induce a prolonged, mild decrease in core body temperature
View Patent ↗The present invention is directed to combination pharmacological treatments that induce a prolonged, modest decrease in core body temperature, to the range of ˜95° F. to ˜98.5° F. (˜35° C. to ˜36.7° C.) to mitigate and delay the early onset and progression of fatal disease processes associated with premature aging, such as those characteristic of progeria (Hutchinson-Gilford Progeria Syndrome, HGPS), Wiedemann-Rautenstrauch syndrome (neonatal progeroid syndrome), Werner syndrome, and other rare disorders characterized by premature aging, and to prolong the shortened lifespan of children afflicted with these diseases. Short-term chronic administration of the pharmaceutical treatments to a person suffering from mild concussion may also have value in ameliorating neurological damage/symptoms associated with mild concussion. Chronic administration of the pharmacological treatments may also have value in normal human populations or in high-risk human populations. Similar benefits may be realized in other mammals such as canines, felines and other non-human species.
1. A method of treating progeria in a patient in need thereof, said method comprising administering a pharmaceutical composition comprising metformin and olanzapine.
2. The method of claim 1 , wherein said metformin and said olanzapine are administered concurrently.
3. The method of claim 1 , comprising administering either:
a) metformin in the morning and olanzapine in the evening; or
b) olanzapine in the morning and metformin in the evening.
4. A method of treating Wiedemann-Rautenstrauch syndrome (WRS) in a patient in need thereof, said method comprising administering a pharmaceutical composition comprising metformin and olanzapine.
5. The method of claim 4 , wherein said metformin and said olanzapine are administered concurrently.
6. The method of claim 4 , comprising administering either:
a) metformin in the morning and olanzapine in the evening; or
b) olanzapine in the morning and metformin in the evening.
7. A method of treating Werner syndrome (WS) in a patient in need thereof, said method comprising administering a pharmaceutical composition comprising metformin and olanzapine.
8. The method of claim 7 , wherein said metformin and said olanzapine are administered concurrently.
9. The method of claim 7 , comprising administering either:
a) metformin in the morning and olanzapine in the evening; or
b) olanzapine in the morning and metformin in the evening.